Posts from ‘October, 2009’

IRVINE, Calif., Oct. 27, 2009 –(HSMN NewsFeed) — SenoRx, Inc. (Nasdaq:SENO ) today announced the appointment of John T. Buhler to the newly created job of President and Chief Operating Officer. Buhler, who currently serves as SenoRx’s Senior Vice Pr…
Devices, Oncology, Personnel
SenoRx, breast cancer

SANTA CLARA, Calif., Oct. 27 (HSMN NewsFeed) — Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced that on September 30th, 2009 the FD…
Devices, FDA
Lumenis, PolyScope, Flexible Endoscope, endoscopy

No statistical difference observed between 2 studied dosing regimens SAN DIEGO, Oct. 26 (HSMN NewsFeed) — According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - …
Biopharmaceuticals, Gastroenterology
UCB, WELCOME trial, CIMZIA, certolizumab pegol, Crohn’s disease

HICKORY, N.C., Oct. 26 (HSMN NewsFeed) — The future of urinary catheter care has arrived. ProtekMed has launched the Tru-flo(TM) urinary catheter valve, an innovative and economical alternative to the standard tube and bag system prescribed by most u…
Devices, Urology
ProtekMed, Tru-flo, urinary catheter valve

Product is Designed To Simplify Procedure and Physician Convenience BLOOMINGTON, Ind.–(HSMN NewsFeed)–Approximately one million women in the United States are rendered infertile by disease in the fallopian tubes, the most common being tubal occlusion …
Devices
Cook Clinical, FluoroSet, salpingography, fallopian tube

Deal will Provide Cephalon New Path Forward for Development of its Tumor Necrosis Factor Inhibitor FRAZER, Pa. and WELLESLEY, Mass., Oct. 26 (HSMN NewsFeed) — Cephalon, Inc. (Nasdaq: CEPH ) and BioAssets Development Corporation (BDC), a privately hel…
Biopharmaceuticals, Mergers & Acquisitions
Cephalon, BioAssets Development Corporation, etanercept

WAYNE, N.J. and EMERYVILLE, Calif., Oct. 23 (HSMN NewsFeed) — Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the companies have begun enrolling patients in an international Phase THREE trial to evaluate…
Biopharmaceuticals, Oncology
Onyx Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Nexavar, sorafenib

Extend Receives FDA 510(K) Clearance STOCKHOLM, Oct. 23–(HSMN NewsFeed)–At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand …
Devices, Oncology, Neurosurgery, FDA
Elekta, Gamma Knife, Perfexion, radiosurgery, radiotherapy

WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.–(HSMN NewsFeed)–Merck & Co., Inc. (NYSE: MRK ) and Schering-Plough Corporation (NYSE: SGP ) today announced that they have received clearance from the European Commission (EC) under the EC Merger Regulation for…
Biopharmaceuticals, Mergers & Acquisitions
Merck, Schering-Plough

Impressive Results of the ARMOUR Medical Trial Demonstrated Low Stroke and Major Adverse Cardiac and Cerebrovascular Event Rates BETHLEHEM, Pa.–(HSMN NewsFeed)–Invatec, a comprehensive innovator of interventional products, today announced that it has…
Devices, Interventional, FDA
Invatec, Mo.Ma, ARMOUR trial, embolic protection